LENZ Therapeutics, Inc. short interest in 2023
In 2023, LENZ Therapeutics, Inc.'s disclosed short interest ran from 1.63% of shares outstanding on 13 Jan 2023 to 2.12% on 29 Dec 2023, a change of +0.49 percentage points. The year's high was 2.31% on 30 Nov 2023 and its low 1.16% on 31 May 2023, averaging 1.76% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.48 days on 31 Oct 2023. Full history: LENZ Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.63% (13 Jan 2023)
- End of year
- 2.12% (29 Dec 2023)
- Change
- +0.49 pp
- High
- 2.31% (30 Nov 2023)
- Low
- 1.16% (31 May 2023)
- Average
- 1.76%
- Highest days to cover
- 18.48 (31 Oct 2023)
- SEC filings marked
- 5
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 1.63% | 1.16 | |
| 31 Jan 2023 | 1.38% | 5.61 | |
| 15 Feb 2023 | 1.42% | 6.66 | |
| 28 Feb 2023 | 1.74% | 2.17 | |
| 15 Mar 2023 | 1.62% | 3.55 | |
| 31 Mar 2023 | 1.51% | 11.03 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 1.42% | 5.74 | |
| 28 Apr 2023 | 1.26% | 3.43 | |
| 15 May 2023 | 1.31% | 6.92 | 10-Q filed |
| 31 May 2023 | 1.16% | 8.00 | |
| 15 Jun 2023 | 1.21% | 9.42 | |
| 30 Jun 2023 | 1.89% | 2.47 | |
| 14 Jul 2023 | 1.98% | 13.04 | |
| 31 Jul 2023 | 1.97% | 11.88 | |
| 15 Aug 2023 | 1.71% | 10.07 | 10-Q filed |
| 31 Aug 2023 | 1.83% | 8.19 | |
| 15 Sep 2023 | 2.07% | 13.25 | |
| 29 Sep 2023 | 2.21% | 6.63 | |
| 13 Oct 2023 | 2.16% | 14.61 | |
| 31 Oct 2023 | 2.12% | 18.48 | |
| 15 Nov 2023 | 2.12% | 6.09 | 10-Q filed |
| 30 Nov 2023 | 2.31% | 14.78 | |
| 15 Dec 2023 | 2.17% | 4.99 | |
| 29 Dec 2023 | 2.12% | 4.54 |
See also: LENZ Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.